High bone mass phenotype in a cohort of patients with Osteogenesis Imperfecta caused due to BMP1 and C-propeptide cleavage variants in COL1A1 by Campanini, E.H. et al.
This is a repository copy of High bone mass phenotype in a cohort of patients with 
Osteogenesis Imperfecta caused due to BMP1 and C-propeptide cleavage variants in 
COL1A1.




Campanini, E.H., Baker, D., Arundel, P. et al. (9 more authors) (2021) High bone mass 
phenotype in a cohort of patients with Osteogenesis Imperfecta caused due to BMP1 and 





This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 
(CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long 
as you credit the authors, but you can’t change the article in any way or use it commercially. More 
information and the full terms of the licence here: https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Bone Reports 15 (2021) 101102
Available online 1 July 2021
2352-1872/© 2021 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
High bone mass phenotype in a cohort of patients with Osteogenesis 
Imperfecta caused due to BMP1 and C-propeptide cleavage variants 
in COL1A1 
E.H. Campanini a, D. Baker b, P. Arundel c, N.J. Bishop c,d, A.C. Offiah c,d, S. Keigwin b, 
S. Cadden b, E. Dall'Ara d, N. Nicolaou e, S. Giles e, J.A. Fernandes e, M. Balasubramanian c,d,f,* 
a Medical School, University of Sheffield, Sheffield, UK 
b Sheffield Diagnostic Genetics Service, Sheffield Children's NHS Foundation Trust, Sheffield, UK 
c Highly Specialised OI Service, Sheffield Children's NHS Foundation Trust, Sheffield, UK 
d Department of Oncology & Metabolism, University of Sheffield, Sheffield, UK 
e Department of Orthopaedic Surgery, Sheffield Children's NHS Foundation Trust, Sheffield, UK 
f Sheffield Clinical Genetics Service, Sheffield Children's NHS Foundation Trust, Sheffield, UK   
A R T I C L E  I N F O   
Keywords: 





A B S T R A C T   
Objectives: Osteogenesis Imperfecta (OI) is a heterogeneous condition mainly characterised by bone fragility; 
extra-skeletal features in OI include blue sclerae, dentinogenesis imperfecta, skin laxity and joint hyper- 
extensibility. Most patients with OI are thought to have a low bone mass but contrary to expectations there 
are certain forms of OI with high bone mass which this study explores in further detail. 
Method: A cohort of n = 6 individuals with pathogenic variants in BMP1 and the C-propeptide cleavage variants 
in COL1A1 were included in this study. Detailed clinical and radiological phenotyping was done and correlated 
with genotype to identify patterns of clinical presentation and fracture history in this cohort of patients. This data 
was compared to previously reported literature in this group. 
Results: 2 patients with BMP1 and 4 patients with pathogenic variants in C-propeptide region in COL1A1 were 
deep-phenotyped as part of this study and 1 patient with C-propeptide variant in COL1A1, showed low bone 
mineral density. In those with an elevated bone mineral density, this became even more apparent on 
bisphosphonate therapy. Patients in this cohort had variable clinical presentation ranging from antenatal pre-
sentation to more of an insidious course resulting in later confirmation of genetic diagnosis up to 19 years of age. 
Conclusions: Patients with pathogenic variants in the C-propeptide region of COL1A1/A2 and BMP1 appear to 
have a high bone mass phenotype with increased sensitivity to bisphosphonate therapy. It is important to closely 
monitor patients with these genotypes to assess their response to therapy and tailor their treatment regime 
accordingly.   
1. Introduction 
Osteogenesis Imperfecta (OI), also known as brittle bone disease, is 
an inherited disorder of the connective tissues causing bone fragility and 
leading to a high fracture risk (Marini et al., 2017). It is a rare disorder, 
present in 1 in 15–20,000 births (Forlino and Marini, 2016), yet it is the 
most common form of inherited bone fragility (Marshall et al., 2016). 
An initial diagnosis of OI is typically made from a combination of 
clinical and radiological findings. Key features on presentation include: 
fractures, growth deficiency, and skeletal deformities, in particular 
bowing of the long bones (other deformities include: flat midface and 
triangular facies, chest wall deformities and scoliosis) (Forlino and 
Marini, 2016). The fractures characteristically present following mini-
mal trauma, in atypical locations and are recurrent (Marom et al., 2020). 
The fracture risk also involves the increased likelihood of vertebral 
compressions (Marini et al., 2017). The severity of the disease can range 
greatly, from mild forms with very few or no fractures, to very severe 
forms presenting with in utero fractures and perinatal death (Sangsin 
et al., 2017). 
There are also common secondary features, which include: blue 
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sclerae, relative macrocephaly, dentinogenesis imperfecta (DI), and 
hearing loss. It has been noted that these secondary features are 
commonly absent in the recessive forms of OI (Forlino and Marini, 
2016). Other potential features include short stature, joint laxity 
(Sangsin et al., 2017), basilar invagination, and cardiac/pulmonary 
problems (Marini et al., 2017). 
The revised Sillence Classification recognises OI types I to V (Van 
Dijk and Sillence, 2014). This describes the different presentations 
caused by variants in the COL1A1 and COL1A2 genes, the IFITM5 gene, 
and some of the recessive forms of the condition (Barnes et al., 2019). 
This classification has since been adapted to include OI types V-XX of OI 
which are associated with variants in other genes. Variants in the BMP1, 
as seen in this cohort, cause Type XII OI (Marini and Dang Do, 2020). 
Type I OI is caused by a null allele in COL1A1 (Barnes et al., 2019) 
and presents with mild features, with infants typically fractures at the 
time they begin mobilising, but these decrease in frequency after pu-
berty. They may have some bowing of the long bones, and commonly 
have blue sclerae. Type II OI is lethal in the perinatal period, commonly 
presenting with many skeletal deformities in utero. Type III OI (pro-
gressive deforming type) is the most severe survivable form, patients 
may sustain hundreds of fractures throughout their life mainly following 
minimal trauma. Other common features in type III OI include denti-
nogenesis imperfecta (DI), chest wall abnormalities and severe scoliosis. 
Type IV OI presents with mild to moderate bone deformity and patients 
typically have white sclerae although they may have been lightly blue at 
birth. Variants in BMP1 cause a moderate to severe presentation and 
patients often have early recurrent fractures and possible long bone 
bowing, despite having a high bone mass (Marini and Dang Do, 2020). 
The most common genes associated with OI are those which encode 
Type 1 collagen (COL1A1 and COL1A2) (Syx et al., 2015); however, 
variants in other genes account for up to 15% of cases (Marom et al., 
2020). This paper discusses 18 genes (from Online Mendelian Inheri-
tance in Man (OMIM)) with variants associated with OI, including: 
BMP1, COL1A1, COL1A2, CREB3L1, CRTAP, FKBP10, IFITM5, MBTPS2, 
MESD, P3H1, PPIB, SERPINF1, SERPINH1, SP7, SPARC, TENT5A, 
TMEM38B, WNT1. These genes are associated with different types of OI 
and have a variety of proposed pathways and mechanisms. Variants in 
COL1A1, COL1A2 and IFITM5 have an autosomal dominant pattern of 
inheritance. Variants in other genes, including BMP1, are responsible for 
autosomal recessive forms of OI, except for MBTPS2 which has an X- 
linked recessive inheritance (Marom et al., 2020). 
Type 1 collagen is made up of two alpha1 chains (encoded for by 
COL1A1) and one alpha2 chain (encoded for by COL1A2). As these genes 
are involved in the synthesis, structure and assembly of type 1 collagen, 
variants can decrease the production (e.g., type I OI) or alter the struc-
ture (e.g., types II to IV OI) (Marini and Dang Do, 2020). Research has 
shown that ~6.5% of patients with OI have variants in the C-propeptide 
(carboxyl terminal propeptide) of type I procollagen (Barnes et al., 
2019). The C-propeptide is important during the synthesis of procolla-
gen and is cleaved extracellularly before the fibril assembly of mature 
collagen (Barnes et al., 2019). A high bone mass has been associated 
with variants involved with the cleavage of C-propeptide (Rolvien et al., 
2018). BMP1 is involved in the processing of type I collagen, cleaving 
the C-propeptide moiety; variants in this gene have been associated with 
high bone mineral density (Marini and Dang Do, 2020). 
A high bone mass form of OI could require a different management 
approach due to the paradigm of clinical presentation. Bisphosphonate 
treatment is the standard treatment for patients with OI and is known to 
increase bone mineral density. However, in the context of high bone 
mass, it is difficult to be precise regarding dosing of bisphosphonate 
treatment. In addition, surgical interventions may be complicated by the 
quality of bone and risk of further fractures thereafter. It is also possible 
that background genetic variants can have an influence on certain OI 
phenotypes, especially with the dominant C-propeptide cleavage 
variants. 
This paper describes the clinical data of patients with variants in the 
BMP1 and C-propeptide of COL1A1/A2 genes, with a focus on those with 
OI associated with high bone mass. 
2. Materials and methods 
2.1. Clinical information 
A cohort of six patients with OI and variants in BMP1 or COL1A1/A2 
was examined in this study. With their informed consent (and their 
parent's where necessary), relevant clinical data were extracted from the 
patients' medical records to put together a history and phenotype. 
2.2. DNA extraction 
Standard extraction methods were used to collect 2 to 5 ml of pe-
ripheral blood from the patients and their parents. In one instance, a 
blood sample was also extracted from the umbilical cord. The QIAmp 
DNA Blood Midi kit (Qiagen, Venlo, The Netherlands) was used to 
extract the DNA from these samples. 
2.3. DNA sequencing 
The samples where then prepared for analysis using Next Generation 
Sequencing. Osteogenesis Imperfecta autosomal dominant and auto-
somal recessive panels were used, containing: NM_006129.5 (BMP1); 
NM_000088.3 (COL1A1); NM_000089.3 (COL1A2); NM_052854.3 
(CREB3L1); NM_006371.4 (CRTAP); NM_001025295.1 (IFITM5); 
NM_022356.3 (P3H1); NM_000942.4 (PPIB); NM_021939.3 (FKBP10); 
NM_152860.1 (SP7); NM_002615.4 (SERPINF1); NM_001235.2 (SER-
PINH1), NM_182943.2 (PLOD2); NM_ 018112.1 (TMEM38B); 
NM_005430.3 (WNT1), NM_000918.2 (P4HB); NM_005032.6 (PLS3); 
NM_014822.2 (SEC24D); NM_003118.3 (SPARC); NM_153365.2 
(TAPT1); NM_022167.3 (XYLT2). 
2.4. Library preparation 
The Covaris E220 sonicator was used for the shearing of genomic 
DNA. The SureSelectCT library system (Agilent Technologies) was used 
to perform the end repair, A tailing and ligation of adaptors. SureSelect 
target enrichment (Agilent Technologies) performed target enrichment 
using custom in house designed probes. Sequencing was performed on 
the Illumina HiSeq using the HiSeq Rapid SBS Kit v2 performing 2 × 108 
base pair paired end reads. 
2.5. Data analysis 
Data analysis was carried out using the Best Practice Guidelines from 
Broad Institute. 
BWA alignment was used in order to map the reads to the human 
reference sequence (GRCH37/hg19) (for additional information see 
http://www.broadinstitute.org/gatk/guide/best-practices). 
A read depth of 30-fold was set as a minimum threshold for exonic 
sequences and intronic sequences up to and including 5 bp from the ends 
of each exon. A read depth of 18-fold was set as the minimum threshold 
got intronic sequences from 6 to 25 bp from the ends of each exon. 
Haplotype Caller (Broad Institute) was used to identify variants and the 
variants were filtered against this in-house polymorphism list. 
2.6. Variant reporting 
Once identified, the variants were compared to cDNA reference se-
quences NM_003118.3 and then assessed with Alamut Visual version 
2.11 QT v5.5.1 (Interactive Biosoftware, Rouen, France). The sequence 
variants were all classified using guidelines for variant interpretation: 
ACMG/AMP (Richards et al., 2015) and ACGS Best Practice Guidelines 
for variant classification 2020 (https://www.acgs.uk.com/quality/ 
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best-practice-guidelines/). As necessary, clinically significant sequence 
variants were confirmed using Sanger sequencing. 
2.7. Clinical reports 
2.7.1. Patient 1 
Patient 1 is a 19-year-old female, born to non-consanguineous par-
ents. She was born at term following an uncomplicated pregnancy and a 
normal vaginal delivery. Her birth weight was 2400 g and her length 
was 62 cm. She is the youngest of three children and both siblings are 
well. Despite frequent fractures, her general health has been fine. She 
was investigated several times for possible cardiac problems, including 
heart murmur and episodes of tachycardia and palpitations, but all tests 
were negative. She has normal intelligence and attended mainstream 
school; she reached menarche at age 13. 
She was diagnosed with type I OI by the Genetics service in Poland. 
She presented with a history of multiple fractures, not consistent with 
injury which had increased in frequency once she became independently 
mobile. It was also reported that she had hypermobile joints and a blue 
tinge to her sclerae. Her first fracture was to her right lower leg at 14 
months old, and by the time she was 5 years old, she had sustained more 
than 10 fractures including multiple fractures to both lower limbs. And 
at age 6, she had bilateral tibial Sheffield rodding. 
She arrived in the United Kingdom with her family at the age of 4 and 
was referred to the paediatric bone disease specialists due to her diag-
nosis. On examination, she had white sclerae and no evidence of den-
tinogenesis imperfecta. She did have bilateral tibial bowing and genu 
valgum with an intermalleolar distance of 10 cm. There was normal 
bone densitometry, and the spinal films had no major findings, although 
three vertebrae in the thoracic spine showed a slight decrease in anterior 
height. 
She was started on pamidronate at age 7 (1 mg/kg/day on 3 suc-
cessive days every 3 months) following a finding of an increasingly 
deformed crush fracture to the thoracic vertebrae. She was also found to 
have Grade I spondylolisthesis at the L5/S1 level. Around this time, she 
was also advised to take over-the-counter supplements to treat vitamin D 
deficiency. Due to the recurrent fractures, she was anxious to stand and 
mainly mobilising by crawling and being carried around the house. For 
longer distances, she was using an attendant propelled wheelchair. A 
few months after commencing pamidronate treatment, her BMD lumbar 
spine had increased from 75th percentile to between the 75th and 98th 
percentile and the BMD for the total body was between the 50th and 
75th. This was deemed to be increasing at a reasonable rate. 
6 months later she was no longer needing a walking aid for the home 
or classroom. She was also now using a manual wheelchair for longer 
distances and becoming more independent with daily activities. She was 
noted to have some hyperextension in distal joints, but this was not 
impacting her functioning and she was able to swim and ride a trike. She 
continued to have valgus at the knees, with an angle of approximately 
20◦. Areal bone mineral density (BMD) by dual energy x-ray absorpti-
ometry (DXA) continued to rise and, at the time of her 4th cycle of 
pamidronate, was above the normal range in lumbar spine (LS) and close 
to the upper limit in the total body less head (TBLH). 
At age 8, she tripped and suffered her first fracture in over a year, to 
her right tibia, which was held in place by the rod. 3 months later, she 
was given a decreased dose of pamidronate (1 mg/kg on 2 successive 
days) as it was noticed that the BMDs of lumbar spine and total body 
were now both above the normal range and it was decided to further 
reduce the dose of pamidronate for the next cycle. After her 8th cycle of 
pamidronate, her DXA scan showed +4.4 and +4.5 standard deviation 
scores (z scores) above the mean for total body less head and lumbar 
spine respectively. Densitometric vertebral analysis showed a good 
vertebral shape and spine radiographs showed mild vertebral height loss 
in two thoracic vertebrae. There was no increase in growth plate width, 
no deformity of the skull bone and there was no evidence to explain the 
large increase in BMD. Pamidronate therapy was continued on the basis 
that the vertebral crush fractures had not completely resolved. 
At age 9, her BMD was still high and it was decided to reduce the 
pamidronate further to 0.75 mg/kg once, every 3 months. The dose was 
reduced again (to 0.5 mg/kg once every 6 months) just before she turned 
12 as the bone density was still above normal with the z score in her 
lumbar spine at +3.0 and total body less head at +1.4. She was switched 
to oral risedronate at 12 years old beginning with 35 mg weekly, 
reducing to alternate weeks a year later. 
At 13 years and 9 months, her lumbar spine BMD z score was +4.3 
(previously +4.7) and TBLH was unchanged at +3.1. By this age, she 
had scoliosis concave to right, believed to be a result of a leg length 
discrepancy (at age 15, her left leg was 3 cm shorter than the right). She 
also had increased lumbar lordosis thought to be due to a low sacral 
kyphosis with a bony shelf. Due to the persisting high BMD despite 
reducing the bisphosphonate to low levels, it was decided to consider 
testing for rarer gene mutations causing OI. Fig. 1 shows her BMD trend 
with age and dense bones on radiographs. 
At 14 years, genetic testing identified that she was homozygous for a 
pathogenic variant in BMP1 and familial testing showed that both her 
mother and father were carriers of a variant each. 
Patient 1 continued to have occasional fractures and at age 14 ½, she 
fractured her distal left humerus after her wheelchair tipped over. By 17 
years old, she had both femurs treated with locked, intramedullary nails 
and both tibiae had telescopic rods which were somewhat bent. There 
was some metalwork in the left elbow remaining from a previous fixa-
tion. There were hemiepiphyseodesis plates in situ in medial distal 
femora bilaterally and proximal medial tibia on the left. 
She was discharged from the bone clinic age 17 and 8 months, taking 
vitamins but no bisphosphonate treatment since age 14 ½. She was 
mainly mobilising with a wheelchair but was able to walk short dis-
tances if needed. She was seeing a dentist every 6 months, but had no DI. 
2.7.2. Patient 2 
Patient 2 is a 12-year-old female, the only child of non- 
consanguineous parents. She was born at 39 weeks following an un-
complicated IVF pregnancy and had a birth weight of 6 lb. 9 oz. She was 
well at birth and breast fed without any problems. She had one episode 
of pneumonia at 8 months but was otherwise well. Other than both 
parents having some degree of hypermobility, there is no other family 
history of note. 
Through her first year of life, she met all developmental milestones. 
The first concerns did not arise until around 16 months when she was 
still not walking; however, this followed her mother's development who 
did not start walking until 18 months, so the parents were not overly 
concerned. The patient was bottom shuffling at 17 months and, at this 
time, it was noted that she was very hypermobile. At 21 months, she was 
still not walking and so was referred to the paediatric clinic. She was 
found clinically to have bilateral dislocated hips. 
She had three operations for her hips, the first of which was at 25 
months, and each operation led to at least 6 weeks of cast immobilisa-
tion. On her third birthday, she had her first fracture to her fibula and 
was casted. Within a week, she presented to A&E with a fracture to the 
left tibia having slipped while leaning against the sofa. Over the next 8 
months, she suffered a further 3 fractures to her lower limbs following 
minimal trauma. Her speech and fine motor development were both 
normal for her age. 
It was initially thought that the fractures were most likely due to 
osteopenia secondary to long periods of immobilisation; however, she 
had extensive investigations and was referred to genetics for a possible 
diagnosis of Ehlers Danlos syndrome due to her joint hypermobility and 
skin laxity. Treatment with pamidronate was offered, but her parents 
declined. 
Investigations included an MRI head and spine, urine amino-organic 
acid, acylcarnitine and Prader Willi Screen; all of which were normal. 
Blood results from FBC, U&E, bone profile, PTH, vitamin D showed that 
PTH was 0.8 pmol/l and vitamin D was 58 nmol/l but the rest were 
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normal. She also had a DXA scan at this time. It showed L2–4 BMD: 
0.728 g/cm2 and TBLH BMD: 0.577 g/cm2, the latter scan included 
numerous metal pins. There was no paediatric reference data but at the 
time it was thought that the lumbar result was likely high for her age. 
At age 4, she was started on pamidronate infusions for about 12 
months. After 3 cycles, her BMD increased considerably, and she had 
chalk stick fractures of the tibiae and fibulae. A clinical diagnosis of 
osteopetrosis was considered; however, bone biopsy findings did not 
support this and showed active osteoclasts and ok bone resorption. On 
examination, she was found to have a high forehead and light blue 
sclerae. She also had generalised joint hypermobility and her skin was 
lax over her abdomen. 
By age 6 and ½, she had had a total of 16 fractures. She was just 
above the 50th centile for weight and between the 50th and 75th cen-
tiles for height. She had also had dislocations of her left shoulder while 
swimming, on three separate occasions, all with spontaneous reduction. 
She was able to walk with a stander and was attending mainstream 
school regularly, also mobilising with a wheelchair. She was having 
weekly hydrotherapy sessions. 
She was referred to Genetics Clinic at 6 years and 9 months in order 
to rule out a possible diagnosis of OI. She had previously tested negative 
for variants in type I collagen genes (COL1A1 and COL1A2), but went 
onto to have further testing which identified her to be compound het-
erozygous for variants in BMP1. Subsequently, familial testing showed 
her parents were carriers of one variant each. 
1 year later, she had had only one further fracture. She was, however, 
still having regular dislocations of her shoulder and hypermobile. She 
was lax at both large and small joints with skin hyperlaxity. She also had 
increased range of movement in both hips and a leg length discrepancy 
which led to scoliosis on standing. 
Quantitative CT imaging showed very high values in the peripheral 
skeleton with a radius z score of +8.7 and a trabecular z score at distal 
radius +9.2. Her lumber spine BMAD Z score was +4.02 and her lumbar 
spine QCT Z score was +3.6. Fig. 2 shows her BMD trend with age and 
dense bones on imaging. 
Throughout her education, she attended mainstream school, with 
one-to-one help for physical education (PE) and later use of writing aids 
including an angled board and Y shaped pencils as she was tired easily 
when writing. She was able to walk short distances independently but 
preferred to wear splints and used her wheelchair for longer distances. 
By 9 years and 8 months, she had 25◦ curvature of the spine and had also 
had recent correction of genu valgum by hemi-epiphysiodesis. She was 
wearing new AFOs and using a recumbent bike for exercise. 
By age 10 ½, she had bilateral intramedullary rods in situ and had not 
had any fractures or dislocations for 2 years, since before her tibial rods 
and her most recent DXA scan (6 months previously), showed the lum-
bar spine Z score to be +1.8. She was taking multivitamins and chole-
calciferol, but no other medications. On examination, she had scoliosis 
concave to the right with the left scapula higher than the right, which 
was confirmed radiologically with no suggestion of segmentation 
anomaly, no syrinx, and no focal marrow oedema. Recent hip films 
showed coxa valga with the right femoral head significantly more 
Fig. 1. A. TBLH* BMD** trend (ages 8 to 17) shows consistently raised BMD. 
B. Anteroposterior radiographs of right (B) and left (C) tibia and fibula aged 5 years and 2 months and 5 years and 8 months respectively. There are transverse 
fractures (acute on the right and healing on the left) of the tibiae and fibulae. Bowing is worse on the right (B). 
*TBLH = total body less head. 
**BMD = bone mineral density. 
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uncovered than the left. 
By age 12, she was walking independently again, however her 
scoliosis was worsening. She was also receiving psychology input due to 
increasing frustration with her condition. 3 months later, she underwent 
correction of her scoliosis. She had slow tooth eruption and dental 
crowding but no DI. 
2.7.3. Patient 3 
Patient 3 is a 12-year-old male who was diagnosed antenatally with a 
severe form of OI and it was believed he would not survive for long 
postnatally. He had 2 older siblings including a half-sister with a history 
of fractures, and he was born following a dichorionic, diamniotic twin 
pregnancy with the female twin unaffected. The labour was induced at 
27 weeks and both babies were born well by normal vaginal delivery and 
no resuscitation was required. Patient 3 had a birth weight of 2440 g and 
was born with multiple fractures of almost every bone in his body. 
He was initially given analgesia to help with discomfort and on the 
day of delivery, he had cast immobilisation applied to four limbs to 
stabilise fractures for pain relief. Initially he was demand fed but had 
been vomiting after feeds and so was given an NG tube. 
He did not die shortly after birth as expected and instead was 
transferred from the neonatal unit to a hospice. He continued to be 
managed with the expectation that he would die; however, a week later, 
he was still alive. It was decided that a palliative approach was not 
appropriate for his phenotype and he would benefit from bisphospho-
nate treatment. He was then transferred to the HDU where he was given 
2 infusions of pamidronate on successive days. At 17 days, he had a 
skeletal survey and clinical phenotyping. He had multiple Wormian 
bones, but a normal head shape and no mid-face hypoplasia. His skeletal 
phenotype was reported to be unusual; he had a mixture of wider, 
slightly crumpled femora and thinner distal segments. Despite multiple 
rib fractures, he did not have any vertebral crush fractures. The high 
number of fractures was thought to be a possible consequence of sharing 
the uterine space with an unaffected twin. 
He had several health complications over the first few months of life, 
including ventilation problems meaning he was still requiring oxygen at 
9 months of age. He was also found to have a patent foramen ovale 
although this had spontaneously closed by the age of 5. His feeding was 
also complicated by gastroesophageal reflux. He was discharged home at 
7 months, although this late discharge was largely due to the family 
finding suitable housing. At 4 ½ years old, genetic testing showed he had 
a de novo variant in the C-propeptide region in COL1A1. 
As a consequence of his diagnosis, his gross motor skills were 
delayed; he was able to roll from side to side in lying position by age 1 
and was crawling on his hands and knees at age 4. While his gross motor 
skills development was delayed, in all other areas, he was meeting 
milestones. There were no concerns regarding his intelligence, and he 
was able to attend mainstream school with 1:1 support. 
By age 5 ½, he had undergone multiple surgeries including osteot-
omies and telescopic rodding bilaterally to the femora and tibiae, to 
attempt to straighten the long bones. By this age he was confident in 
using a wheelchair for mobilising. He was also wearing glasses due to 
astigmatism and was under the dentists for a diagnosis of dentinogenesis 
imperfecta. A year later he was investigated for possible sleep apnoea 
following reported lengthy pauses in breathing with associated pallor; 
however, this was found to not be an issue. 
His BMD was constantly low, with a DXA scan at age 5 ½ showing the 
lumbar spine BMD to be 0.483 g/cm2 (Z score of −2.0) and the total 
body less head to be 0.443 g/cm2 (Z score of −1.1). This further 
decreased to −2.2 and −1.8 respectively a year later and at 7 years old, 
the L2–4 BMD Z score was −2.7 (BMAD Z score −3.3) and the TBLH Z 
score was −1.6. 
At 7 years and 3 months, while in plaster following a recent revision 
surgery for the tibia rodding, he was able to stand with the support of the 
Fig. 2. A. L1–L4 BMD trend shows BMD consistently high or at the upper limit of normal. 
B. Lateral radiograph of the right tibia and fibula aged 6 years shows a similar transverse mid-tibial shaft fracture as seen in Patient 1, with mild bowing of the tibia. 
C. Anteroposterior radiograph of the chest at 12 years and 4 months. Endotracheal tube and left internal jugular venous line are in situ. There has been development 
of a thoracolumbar scoliosis, in the absence of vertebral fractures. Note the unusual shape of the lateral ends of the clavicles (seen only in this patient). 
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therapist for the first time and was able to take some steps with a walker. 
3 months later, he was switched from pamidronate to zoledronic acid 
(0.04 mg/kg for one day every 6 months) as there were difficulties 
around cannulation and it was thought he would benefit from fewer 
infusions. It had also been noted that he had been developing blisters on 
the tips of his fingers following the treatments. However, the zoledronic 
acid was found to not be as effective and so he was switched back again 
shortly afterwards. The dose was later changed to 1.5 mg/kg on one day 
to minimise the cannulation required. 
He began to encounter problems where he had outgrown the previ-
ous corrective surgeries. At 8 years of age, he was found to have 
outgrown the intramedullary wire in his right forearm which had begun 
Fig. 3. A. DXA performed at 9 years and 4 months shows a BMD below 2SD of normal for age and sex (this is the only patient in our cohort with low BMD). 
B. Anteroposterior radiograph of the chest aged 1 day. The bones are slender. There are multiple acute and healing rib fractures, an acute fracture of the left humerus 
and healing fractures of the right humerus and both clavicles. There were also fractures of the lower limbs (not shown). The acute fractures may have been sustained 
during the birth process; however, the healing fractures will have been sustained in utero. 
C. Vertebral fracture assessment (lateral spine DXA) shows multilevel mild and moderate vertebral body collapse of thoracic and lumbar spine. 
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to irritate the soft tissue, causing him significant pain. At 9 years and 3 
months, pain in his left buttock showed a palpable rod which required 
revision rodding. Just before he turned 10, he was having slight pain 
over his right proximal humerus and a radiograph confirmed that the 
telescopic rod had cut out. He subsequently underwent removal of the 
rod and diaphyseal osteotomy with revision rodding. 
Patient 3 also had bone local mechanical properties assessed on a 
bone specimen mainly of cortical bone, obtained from the upper limb 
(hardness and elastic modulus) assessed using nano-indentation tests 
(Pepe et al., 2020) tested in different locations (192 tests within different 
regions of the specimen). The results showed high heterogeneity in the 
local material properties of the bone in different locations, with coeffi-
cient of variations in the range of 43–48% (Elastic modulus equal to 
11.20 ± 5.39 GPa; Hardness equal to 0.49 ± 0.21 GPa). The elastic 
modulus measured in the bone was 30–40% lower than the average 
values found in bones extracted from the lower limb or iliac crest of OI 
type I or type III young patients (3–18 years old) (Albert et al., 2013; Fan 
et al., 2007). This difference could be due to the different disease, the 
tested anatomical site and/or the age of the patients. Nevertheless, given 
absence of normative paediatric literature and analysis of only one 
sample, it was difficult to draw any firm conclusions from this data. 
At 9 ½ years, his DXA scan showed a TBLH BDM of −2.8 (previously 
−1.5) (Fig. 3). Densitometric vertebral fracture assessment (VFA) 
showed little change, but possible worsening of shape of L2 and L3 
vertebrae and there were still multiple vertebrae with loss of height. At 
this age, he was mobilising using a walking frame and his spine was 
straight with no obvious tenderness. 
At 10 years and 3 months, he was noted to have bilateral thyroid 
nodules however they appeared benign and microcystic and it was 
decided that there was no need for further investigations unless indi-
cated by a change in biochemistry results. At this age, his BMD was still 
at the lower range of normal. His L2–4 BMD z score was −2.1 (BMAD 
−2.0) and his total body less head BMD z score was −0.6 (BMAD −2.6). 
VFA showed a continued mild-moderate loss of height of several 
thoracic vertebral bodies, moderate loss of height of L2, and marked loss 
of height of L3 and L4. His weight was 17.95 kg and his length was 97.5 
cm and 102 cm (due to leg length discrepancy). His spine was straight. 
By age 11, he had further interventions including trimming and 
reinsertion of the K wire which was eroding at the elbow following 
revision rodding of the right ulna. This rod was later removed. He had 
pain in the left hip due to left migration of the femoral telescopic rod 
which required readjustment. Recent scans had shown no spondylolysis, 
but an almost parallel sacrum and a further significant bend in the lower 
sacrum coccyx. 
At 11 ½ years old, he had radiological investigations following a 
possible finding of hyperextension of C2 and C3 on a skull radiograph a 
year previously. He was also occasionally having pain at the back of the 
neck, associated with some headaches. It was reported that the tip of the 
dens was at C2 and he had a wide anterior gap. It was decided that there 
was no need for neurosurgical intervention at that time. 
A month later, he suffered an undisplaced horizontal fracture 
through his right radius while reaching out for a video game controller 
and he was placed in a below the elbow soft cast. 12 weeks later, 
radiograph showed fractures to the distal 1/3 shaft of radius and ulna 
which were not uniting and causing deformity and required a splint. By 
11 years and 10 months, the deformity had worsened although the non- 
union was painless. His arm was neurovascularly intact and so surgical 
correction was planned for. 
2.7.4. Patient 4 
Patient 4 is a 9 year old male born to non-consanguineous parents. 
He was born at 40 + 4 weeks following an uncomplicated pregnancy and 
normal vaginal delivery. His birth weight was 3855 g and he had no 
clinical evidence of fractures. His father had recently been diagnosed 
with type 1 OI following familial genetic testing due to a diagnosis in his 
nephew. Therefore, Patient 4 had pre-symptomatic testing of the cord 
blood at birth which showed him to be heterozygous for a variant in 
COL1A1, like others in his family including his father and grandfather. 
Affected members of the family appeared to follow a similar pattern of 
fractures at birth and then none until age 15. 
At 3 days old, the patient was referred with swelling to the right thigh 
and was found to have a fracture of the right femur, which was 
confirmed on radiographs and managed conservatively. At 4 weeks old, 
he attended hospital again with a fracture of the left distal humerus after 
his left arm had got caught in his vest sleeve. At this time, he also had a 
skeletal survey which showed an old fracture to the right femur with no 
callus, a fracture to the right radius with some callus and a fracture to the 
6th rib with some callus, as well as two new fractures, including the one 
to the left humerus and one to the right femur (Fig. 4). He was admitted 
and placed in gallows traction for 11 days and then a pelvic harness. At 
6 weeks, he was started on pamidronate at the standard dose of 0.5 mg/ 
kg. 
At 6 months, he had sustained no further fractures. He was now 
sitting unsupported for short periods, was comfortable pushing up from 
prone, but was not yet pulling to stand. He was fully weaned and 
growing well with a weight of 8.8 kg (50th centile) and a length of 69 cm 
(75th centile). On examination, he had blue sclerae and some flattening 
of the left side of the occiput. His teeth, that had erupted appeared 
normal, he had normal shaped facies, normal chest shape and a straight 
spine with no tenderness. Lateral spine films showed minor loss of height 
in two of the thoracic vertebrae and he had a mild degree of bowing of 
both femora, but no other long bone deformities. 
Other than a single skull fracture at 11 months, Patient 4 had no 
further fractures until he was 2 years old; he fractured his right femur 
while at soft play and was treated with a fixed rod. He was standing and 
cruising around furniture at 11 months and by 16 months, his devel-
opment was age appropriate. A DXA scan at 13 months showed his 
lumbar spine BMD to be 0.405 g/cm2. There was little change in the 
appearance of the vertebrae and persisting loss of height in two thoracic 
vertebrae. At 22 months, his spine was straight, he had good muscle bulk 
and there was no evidence of long bone deformity. A lateral radiograph 
showed that the appearance of the spine had improved although there 
was still mild reduction in the vertebral body height in the thoracic 
vertebrae and L3. There was also spondylolysis at L5/S1 but no 
spondylolisthesis. 
At age 2 ½ he was speaking words, but no sentences. He lacked 
approximately 5◦ knee extension on the right following the rodding. He 
also lacked end of range supination at the elbows bilaterally. He was 
switched to zoledronic acid with a dose of 0.025 mg/kg as a single 
infusion once every 6 months. This was due to the lower frequency of 
infusions as there were difficulties with cannulation; at 4 years, this was 
switched again to oral risedronate 35 mg once fortnightly. 
At 4 years old, he had another DXA scan which showed L2–4 BMD to 
be 0.743 g/cm2 (increased from 0.663 g/cm2 10 months previously) and 
TBLH BMD to be 0.592 g/cm2 including a metal rod in the right femur 
(increased from 0.561 g/cm2). He had undergone removal of fixed rods 
and telescopic rodding of the right femur 7 months previously. Lateral 
spine radiography showed no definite loss of height of any vertebrae and 
lateral skull radiography showed no basilar invagination. It was soon 
noted that his bone density was relatively high for his age and the sur-
geons had commented that his bones were particularly dense. He also 
had delayed healing of the osteotomy and it was also noted that the 
patient's father had had problems with delayed healing and it had taken 
14 surgeries to get his right femur to heal properly. It was confirmed that 
patient 4 had a paternally inherited COL1A1 C-propeptide variant. 
After a repeat DXA scan showed further increase in BMD, the deci-
sion was made to discontinue the risedronate. He had had no further 
fractures having been off risedronate for 3 months following surgery for 
femoral de-rotation on the right side with plate fixation, and the sur-
geons again commented that his bone was difficult to drill through due 
to hardness. It was decided to consider reintroduction of bisphospho-
nates approaching growth spurt given the family history of femoral 
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fractures in teenage years. At 5 years, his DXA scan showed another 
increase in BMD with L2–4 at 0.792 g/cm2 and TBLH at 0.674 g/cm2. 
By 5 ½ years old, Patient 4 had had a stress fracture in the right 
subtrochanteric area with malunion and de-rotation osteotomy subse-
quently. Medial cortical healing was almost complete after removal of 
the de-rotation plate, but there was still a lateral cortical defect. He was 
not in any pain but was walking with a short leg gait with segment 
deficient being on the contralateral side. On examination, he was short 
in the left tibia by an estimated 15 mm which accounted for his limp 
when walking and his right knee had a small, fixed flexion contracture of 
about 10◦. His hip exam was normal and he was able to play football 
with his father and participate in school PE. His DXA scan showed a 
slight decrease in BMD; L2–4 was 0.777 g/cm2 (Z score +1.8) and TBLH 
was 0.662 g/cm2 (Z score +3.1). VFA showed preservation of vertebral 
height. 
Patient 4 continued to have repeat DXA scans (Fig. 4): At 6 years old 
the L2–4 and TBLH Z scores were +1.9 and +1.5 and at 7 years old they 
were +1.9 and +2. He had no further fractures and continued to show L4 
and L5 Grade I spondylolysis. There was good disc height, slip angle was 
acceptable, sacral promontory was reasonable and it was decided to 
observe for symptoms and risk of slip progression. 1 month later, he 
underwent revision rodding of the right proximal femur with the plan 
being to start graded weight bearing 2 months later. 
At 8 years and 3 months, he had a recent re-fracture of his right 
femur with rod in situ. He tripped and fell at school onto his right knee 
and bent the intramedullary rod. He underwent right revision rodding of 
the femur with corrective osteotomy and plating a few months later and 
was mobilising with crutches 6 weeks later. By 8 years and 11 months, 
he was healing well, walking inside the house without support; using 
crutches for short distances outside the house and his wheelchair for 
longer distances. His most recent DXA scan showed L2–4 +0.6 (previ-
ously +1.9), TBLH +2.0 (previously −0.1). VFA showed persistent loss 
of height in at least two thoracic and two lumbar vertebrae but there was 
probable minor improvement in one thoracic vertebra. He had occa-
sional discomfort in his back after prolonged sitting where leaning for-
ward and he had a recent fracture to his toe, but on clinical examination 
his spine was straight. The decision was made to restart the risedronate 
at a dose of 35 mg once weekly due to the persistent loss of vertebral 
height and the fact that the BMD was now decreasing. 
2.7.5. Patient 5 
Patient 5 is a 10 year old male born following an uncomplicated 
pregnancy to a 19 year old mother with known OI with an identified 
COL1A1 variant. She contacted the genetics service at 6–7 weeks preg-
nant, aware that there would be a 50% chance of passing on the con-
dition and unsure of whether or not to continue with the pregnancy. She 
was offered a test to find out whether the baby had OI but declined, and 
decided to continue with the pregnancy. 
Patient 5 was born via c-section at 38 weeks. He was healthy at birth 
and weighed 3400 g. He was active and alert with no external stigmata 
of OI. Examination at 1 month showed that he had blue sclerae and there 
was laxity of the small joints, but rest of his examination was normal. 2 
months later, he had normal range of active movements although he had 
mild head lag in the sitting position. His weight was tracking around the 
25th centile. By 10 months, he was meeting most developmental mile-
stones. He had some reluctance to crawl but this was put down to 
spending so much time in a walker. He had had no fractures or dislo-
cations. There was no deformity of long bones, his spine was straight, 
and a previous lateral spine film showed no crush fractures. He had some 
flattening at the back of his head and hyperlaxity of joints, especially the 
Fig. 4. A. TBLH BMD trend (ages 5 to 9) shows raised BMD between 5 and 8 years, reducing to normal at 9 years of age. 
B. Anteroposterior chest radiograph at 1 month of age shows slender ribs, with some healing fractures of the right 7th and left 2nd and 6th ribs. 
C. Anteroposterior radiograph of the right femur at 1 month of age shows a healing fracture, possibly sustained at birth. 
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wrist, ankle and hips, but had reasonable trunk control. He still had blue 
sclerae and it was thought that he most likely had inherited the familial 
OI variant. 
At 16 months, he had a DXA of his Lumbar Spine (LS) which showed 
a BMD of 0.334 g/cm2. He was also noted to have a degree of pronation 
in ankles and his joints were hypermobile. He was walking by 21 
months. He sustained his first fracture at 2 years and 2 months following 
an accident while playing with his parents. He fractured his left femur 
and in a cast for 5 weeks (Fig. 5). Soon after, he sustained a possible 
hairline fracture of the 2nd metatarsal. About 2 years later, he sustained 
a metadiaphyseal fracture of his 5th right metatarsal. He sustained no 
other fractures until he was 5 years and 8 months, when he fractured his 
left tibia. 
At 2 ½ years old, he was seen to have an increase in BMD of lumbar 
spine and a deterioration in vertebral morphology, with at least 3 
vertebrae having lost some height. He was started on pamidronate a few 
months later at a dose of 1 mg/kg on each of 3 successive days. 
By 3 ½ years old, he was noted to have very pronated feet and hy-
perextension of the knees (20◦), with poor lower limb alignment. His 
most recent DXA scan showed LS BMD to be 0.531 g/cm2 (increased 
from 0.461 g/cm2 6 months previously) and TBLH BMD to be 0.432 g/ 
cm2 (increased from 0.392 g/cm2). Lateral skull radiography showed no 
basilar invagination. Possible fusion of the posterior elements of C2 and 
C3 was noted as an incidental finding. Lateral spine radiography showed 
anterior loss of height in several thoracic vertebrae. He was also com-
plaining of back pain in the weeks leading up to his pamidronate 
infusion. 
At 4 years old, he was able to cycle his bike independently with 
stabilisers; however, he had some degree of limitation of activity 
compared to his peers and his general wellbeing had been impacted by 
frequent tonsillitis and ear infections. He also had bilateral foot calca-
neovalgus deformity and was wearing orthotics regularly. 
He started mainstream primary school at age 5. VFA showed a 
continuing decrease in anterior height of 3 or 4 thoracic vertebrae. His 
lumbar spine z score was +0.9 and his total body less head z score was 
+2.1. 6 months later, following his 12th cycle of pamidronate, a repeat 
DXA scan showed his lumbar spine z score had increased to +1.3, but his 
TBLH had decreased to +1.6. VFA showed a decrease in anterior height 
of vertebrae at T4, T7 and T10 without any evidence of a slip in the 
lumbo-sacral region and it was thought that the vertebral shape was 
slowly improving. 
At 5 years 8 months, he suffered a left tibial fracture, for which he 
had a closed reduction and insertion of telescopic rods. 2 months later, 
he had a unicortical re-fracture of the osteotomy site left middle 1/3rd 
tibia with no bend in the rod. 
At 6 years and 2 months, he sustained a mid-shaft fracture to his right 
tibia after tripping over a carpet edge at school. He underwent telescopic 
rodding of the right tibia. 
He had trialled switching to zoledronic acid, but this had less 
symptomatic benefit, so he reverted back to pamidronate. His DXA scans 
continued to show slightly fluctuating z scores and pamidronate was 
decreased to 1.5 mg/kg at 7 years 3 months. His z scores for L2–4 at 6 ½ 
years, 7 years, 7 ½ years and 8 years were +1.1, +1.7, +1.5, and +1.5 
respectively and scores for TBLH were +2.5, +2.7, +2.7, and +2.2. Over 
this time, lateral spinal radiography continued to show minimal loss of 
height in T5-T7 and L3, although there had been slight improvement in 
the height of T4. 
At 8 years and 1 month, he underwent a right tibia rod exchange as it 
was failing to telescope. 1 month later, he had a left mid shaft femoral 
fracture and was treated with an intramedullary rod. At 8 years 7 
months, Patient 5 was found to be heterozygous for c.3584del patho-
genic variant in COL1A1, like his mother. His younger brother was also 
tested for the variant, but was found to be negative. He continued on the 
pamidronate until he was 10, when he was switched to oral risedronate 
at a dose of 35 mg once fortnightly. This was due to need to reduce 
unnecessary visits to the hospital. 
By 10 years and 3 months, his rods were no longer telescoping. He 
was using insoles for fallen arches and had a slight limb length 
discrepancy of the right leg being 1.5 cm shorter than the left. It was also 
noted that he had subtle genu valgum, like his mother and had lost some 
internal rotation of his left hip which was noticeable on walking but was 
not causing him any pain. His most recent DXA scans showed z scores for 
the Lumbar Spine of +2.0 (from +1.6) and total body less head of +2.3 
(from +1.8). VFA showed mild loss of height and his spine was straight. 
Fig. 5. A. TBLH BMD trend (ages 5 to 10) shows consistently raised BMD. 
B. AP pelvis at 2 years and 1 month shows an acute fracture of the left proximal femoral shaft. 
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2.7.6. Patient 6 
Patient 6 is the 30-year-old mother of Patient 5. At age 13, she was 
found to have a COL1A1 variant along with a clinical diagnosis of OI. 
There is also a more significant family history of OI. It was understood 
that there was a history of fractures on her father's side involving her 
father, aunt and cousin, but there was limited information on this. 
Unfortunately, there was not much information available on her 
early history and presentation of OI. She has had many fractures in her 
life and while her eldest son (Patient 5) was growing up, she frequently 
encountered problems regarding her ability to carry him and push his 
buggy due her own diagnosis. 
At 10 months, it was noted that she had congenital musculoskeletal 
anomalies, but these were not otherwise specified. At 4 years and 5 
months, she fractured her tibia and fibula, and 6 months later she 
fractured her radius and ulna. Since then, she has suffered multiple 
fractures to bones in her foot including recurrent fractures to her right 
and left 5th metatarsals. 
She had a routine echocardiogram just before she turned 29 due to a 
perceived risk of valve and aortic root diseases associated with OI but 
this was normal, and she was scheduled for a repeat in 5 years-time. She 
was being administered pamidronate from age 10 to 18 and stopped 
when she found out that she was pregnant. When she was 19 ½ years old 
her son (Patient 5) was born following an elective caesarean section. Her 
most recent fracture was 2 years previously to the 5th metatarsal. The 
most recent imaging of her lumbar spine (at 18 years and 10 months) 
showed no crush fracturing deformity, spondylosis or spondylolisthesis 
below T10. She had suffered with severe back pain for a long time and 
found that this was much worse following the lumbar puncture she had 
for the caesarean section. 
Over the following years, she continued to have severe back pain 
requiring analgesia. At 20 years old, she was noted to have no spinal 
tenderness, but had exaggerated lordosis and the movement of her 
lumbar spine was limited. She had no reduction in the height of verte-
brae and her BMD was stable (Fig. 6). At 21 years, her lumbar spine and 
total hip scores were 0.8 and 1.4, which had showed no significant 
change from the results 2 years previously. She had a long-standing 
problem of not consuming enough dairy in her diet and so was regu-
larly taking calcium and vitamin D supplements since the birth of her 
first son. 
She suffered another fracture to her left 5th metatarsal at age 22 after 
stumbling; she decided that she wanted to restart bisphosphonates and 
was started on zoledronate at 5 mg. This was not continued as it only 
Fig. 6. A. TBLH BMD trend (ages 9 to 18) shows consistently normal BMD, trending towards the upper end of the normal range with increasing age. 
B. Lateral spine radiograph aged 18 years and 9 months demonstrates mild loss of height of mid thoracic vertebral bodies and dense vertebral end plates consistent 
with bisphosphonate therapy. 
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improved her symptoms for a few weeks. She later decided not to start 
on other bisphosphonates as was having problems finding a method of 
contraception that worked for her and did not want to risk getting 
pregnant while on bisphosphonates. 
At 27 years of age, she gave birth to her second son following a 
caesarean section. He was well at birth with no signs of OI and was found 
to be negative for the familial variant for OI. In both cases, she found 
that her back pain increased following the pregnancy. 10 weeks after 
delivery, her lumbar spine and total hip z scores were 1.0 and 1.8 
respectively, which showed no significant change from the results three 
years previously. 
By age 30, she continued to have frequent generalised aches and 
pains (which was improving following regular physiotherapy exercises), 
as well has problems with her left knee when kneeling, and her left foot 
around the site of previous stress fractures. Her most recent lumbar spine 
and total hip scores were 0.8 and 1.7 respectively, which again showed 
no significant change from 18 months previously. 
3. Results 
3.1. Patient 1 
Genetic testing identified Patient 1 to be homozygous for the 
c.355C>T missense variant, predicted to result in a p.Arg119Trp amino 
acid change in exon 3 of BMP1. Further testing showed that both her 
mother and father were heterozygous for the c.355C>T variant. 
3.2. Patient 2 
Genetic testing showed Patient 2 to be compound heterozygous for 
variants in BMP1. She had a c.1148G>A missense variant in exon 9 
predicted to result in the p.Arg383Gln protein change and a c.1293C>G 
nonsense variant in exon 10 predicted to result in the replacement of the 
tyrosine at position 431 with a premature termination codon. These 
mutations had not previously been reported but other mutations in this 
gene were known to be associated with OI. 
Subsequently, her parents were also tested for the variants. Her fa-
ther was found to be heterozygous for the c.1148G>A variant and her 
mother was found to be a heterozygous for c.1293C>G variant. 
3.3. Patient 3 
Patient 3 was found to be heterozygous for a c.4160C>T variant in 
the C-propeptide region of COL1A1 predicted to result in a p.Ala1387Val 
missense amino acid change. This variant had been previously reported 
in one family with a recurrence of type IIC OI although the functional 
effect was undetermined and in silico analysis did not support the 
pathogenicity. Further familial testing showed that this variant to be de 
novo. 
3.4. Patient 4 
Pre-symptomatic testing of the cord blood, showed Patient 4 to be 
heterozygous for the familial c.4343G>A, p.Gly1448Asp pathogenic 
missense variant in exon 51 of COL1A1. 
3.5. Patient 5 
Patient 5 was found to be heterozygous for a c.3584delG deletion 
variant, predicted to result in a p.Gly1195fs frameshift in COL1A1. This 
is the same variant found in his mother (Patient 6). 
3.6. Patient 6 
Patient 6 was found to be heterozygous for a c.3584delG deletion 
variant located in the C terminal telopeptide domain of COL1A1, not 
previously reported in literature. It was predicted to generate a shift in 
the reading frame (resulting in a p.Gly1195fs) and produce premature 
termination codon 44 amino acids downstream. Similar variants have 
been associated with OI of variable phenotype. 
4. Discussion 
COL1A1 and COL1A2 genes (located on chromosomes 17q21.33 and 
7q21.3 respectively (OMIM)) encode for three peptide chains: two proαI 
chains and one proα2 chain. Together, these make up the type I pro-
collagen molecule, which is the precursor for type I collagen. Each of the 
chains has a central triple helix and they combine into a trimeric 
structure (Cundy et al., 2018). The amino (N) and carboxyl (C) terminal 
propeptides are then cleaved and the collagen molecules are arranged 
into fibrils (Sangsin et al., 2017). The BMP1 gene (found on chromosome 
8p21.3) encodes BMP1 and mTLD which are two of the four proteins 
involved in the cleavage of C-propeptide from procollagen (the others 
are mTLL1 and mTLL2) of which, BMP1 was found to have the greatest 
cleavage activity (Sangsin et al., 2017). In addition, it also affects 
regulation of TGFβ and activins which impact osteoclastogenesis. Inac-
tivating variants in BMP1 have been shown to decrease the levels of both 
BMP1 and mTLD and therefore impairing the cleavage of the C-pro-
peptide (Cundy et al., 2018). 
It has been explained that the type I procollagen C-propeptides are 
involved in both the intracellular procollagen assembly and the extra-
cellular assembly of collagen fibrils (Symoens et al., 2014). It is needed 
for the regulation of bone mineralisation (Syx et al., 2015) and is 
involved in regulating the expression of collagen genes via negative 
feedback (Barnes et al., 2019). One study found that where there was C- 
propeptide retention, the structure of type I collagen fibrils was less 
organized (Syx et al., 2015). The C-propeptide domains are also 
important in the selection and association of proα chains (Symoens et al., 
2014). 
Variants in the collagen I genes (COL1A1 and COL1A2) are the most 
common in OI (Marshall et al., 2016). With the most common variant 
being glycine substitutions in the helical domain (Marshall et al., 2016). 
This variant is known to cause problems with the structure of collagen 
and has been associated with the more severe forms of OI. The other 
main variants are nonsense mutation which causes there to be less 
normal collagen (Hoyer-Kuhn et al., 2015). C-propeptide variants ac-
count for only ~5% (as of 2014) of the variants that have been identified 
in type I collagen (Symoens et al., 2014). 
Variants in the COL1A1/A2 genes have been shown to lead to 
varying phenotypes. These have been classified into OI types I–IV and 
these vary from lethal in the neonatal period (type II) to more mild forms 
(types I and IV) (Marini and Dang Do, 2020). The phenotypes of patients 
with a C-propeptide variant in these genes can also be very varied, which 
is shown in the patient descriptions of this cohort. This is also supported 
in the literature, with examples of mild to lethal types of OI in patients 
with heterozygous variants in the C-propeptide regions (Lindahl et al., 
2011). There are also examples of patients with variants in the type I 
procollagen C-propeptide domain or in the C-propeptide cleavage sites 
of the proα1 and α2 chains who have high bone mass (Syx et al., 2015). 
The cohort reported here includes descriptions of 4 patients from 3 
different families with C-propeptide variants in the COL1A1 and 2 pa-
tients with BMP1 variants. Table 1 describes the clinical phenotype of 
BMP1 patients in this cohort in comparison to published literature. 
Table 2 describes the cohort of patients here with COL1A1 variants in 
comparison to previously published literature on C-propeptide variants 
in association with high bone mass while Table 3 gives an overview of 
their genotype and variant classification based on ACMG criteria 
(Richards et al., 2015; ACGS Best Practice Guidelines for variant clas-
sification 2020 https://www.acgs.uk.com/quality/best-practice-guidel 
ines/). 
The severity of their phenotypes was very different from case to case. 
Patient 3, who was de novo heterozygous for variant in COL1A1, had a 




Clinical phenotype in patients with BMP1 variants and comparison to published literature.  
Patient 1 2 7 8 9 10 11 12 13 
Family 1 2 6 7 7 8 9 10 10 
Source This cohort (Sangsin et al., 
2017) 
(Pollitt et al., 2016) (Syx et al., 2015) 
Age (at time of 
publication) 
19 12 6 14 5.2 43 31 47 45 
Sex F F M M F M M M M 
Ethnicity Polish Northern European Thai Asian Asian Caucasian Portuguese Scottish Scottish 
Consanguinity No No No Yes Yes No No No No 
Family history None Parents have 
hypermobility 
no Sister (patient C) Brother (patient B) no Younger brother Brother (patient G) Brother (patient F) 
Pregnancy Uncomplicated IVF 
Uncomplicated 
Data unavailable Data unavailable Data unavailable Data unavailable Data unavailable Data unavailable Data unavailable 
Gestation Term 39 weeks Term 37 weeks 36 weeks Full term Data unavailable Data unavailable Data unavailable 
Birth weight 2400 g 2900 g 3600 g 2500 g 2420 g 3650 g Data unavailable Data unavailable Data unavailable 
1st fracture 14 months 












Birth Long bone fractures 
shortly after walking 
Long bone fractures 
shortly after walking 
Bisphosphonates started 
(age) 
7 years 4 years 8 months ~6.5 years 3 years None Not reported Not reported Not reported 































Homozygous Homozygous Compound 
heterozygous 




Cognitive development Normal Normal Normal Not reported Normal Normal Not reported Not reported Not reported 
Motor development  Delayed – not walking 
at 21 months 
Early development 
was normal 
Not reported Normal Delayed Not reported Not reported Not reported 
Motor skills Mainly using 
wheelchair, but can 
walk for short distances 
Able to walk 
independently 
Able to walk until 6 
years 
Not reported Not reported Never able to walk. Dependent on 
wheelchair for all 
mobility 
Wheelchair dependent 
at around 14y 
Able to walk very short 
distances supported 
Age matched DXA Z 
score (pre- 
bisphosphonates) 
None measured 0.728 g/cm2 (aged 4 
years, no Z score 
available) 
Not reported −0.9 (aged 6 
years) 
Not reported Not reported Not reported Not reported Not reported 
Age matched DXA Z 
score (post- 
bisphosphonates) 
+4.3 (aged 13 years 9 
months) 
+4.02 (aged 7 years 9 
months) 
Not reported 0.3 (aged 14 
years) 




Not reported Not reported Not reported 
Sclerae Blue then white Light blue then white White White Grey Blue then white White White White 
Teeth No DI Dental crowding and 
slow tooth eruption. 
No DI 
No DI No DI but dental 
decay 
No DI Opalescent teeth Translucent and fragile 
with brown 
discolouration 
Not reported Not reported 
Hearing Normal Normal Not reported Normal Normal Normal Normal Normal Normal 
Vision No problems No problems Not reported Not reported Not reported Mild myopia Not reported Not reported Not reported 
Hypermobility + +++ Not reported Fingers Fingers Mild in fingers No Not reported Not reported 
Scoliosis Concave to right due to 




correction at age 12 
Not reported Not reported Not reported Severe 
kyphoscoliosis 
Mild kyphosis Moderate Very mild 
Vertebrae Minimal height loss in 
two thoracic vertebrae  









Not reported Not reported  
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Patient 14 15 16 17 18 19 20 21 22 23 24 25 
Family 11 12 13 14 14 15 15 16 17 18 19 20 
Source (Xu et al., 2019) (Cho et al., 2015) (Choksi et al., 
2021) 
(Asharani et al., 2012) (Martínez-Glez et al., 2012) (Valencia 
et al., 2014) 
(Fahiminiya et al., 2015) 
Age (at time of 
publication) 
15  7 11 7 15 5 2.8 17.4 28.8 22.6 8.1 
Sex M F M M F F M M F F M F 
Ethnicity Chinese Korean Hispanic Turkish Turkish Egyptian Egyptian Pakistani French Canadian French Canadian French 
Canadian 
French Canadian 
Consanguinity No No No Yes Yes Yes Yes Yes No No No No 








No No No No No 




Unremarkable Not reported Not reported Not reported Not reported 
Gestation Full term NVD at 37 weeks Full term Not reported Not reported NVD full term Not reported Not reported Not reported Not reported Not reported NVD at term 
Birth weight 3300 g 3400 g Not reported Not reported Not reported Not reported Not reported 2935 g Not reported Not reported Not reported 3460 g 
1st fracture 22 months left 
femur 
Immediately after 
birth left humerus 
2.5 years right 
tibia 
23 months 14 months Immediately 
after birth left 
tibia 
At birth, both 
femora 
4 months 4 years 0.8 years 2.5 years Birth 
Bisphosphonates 
started (age) 
Treated for 12 
months. Not 
reported when. 





c.C505T c.34G>C c.34G>C c.747C>G c.747C>G c.34C>G c.*241T>C c.*241T>C c.*241T>C c.*241T>C 
c.2107G>C 
Protein change p.Asp442Tyr p.Met270Val 
p.Ala433Ser 
















Normal Normal Normal Not reported Not reported Not reported Normal 
Motor development Sit at 7 months 
Walk at 15 
months 
Delayed. Not able 
to sit unsupported 
at 12 months 
Moderately 
delayed 
Not reported Not reported Delayed Delayed Delayed Not reported Not reported Not reported Delayed. Walking 
at 20 months 
Motor skills Not reported Not reported Not reported Not reported Not reported Not able to stand 
unsupported 
Not able to 
stand 
unsupported 
Not reported Not reported Not reported Not reported Not reported 
Age matched DXA Z 
score (pre- 
bisphosphonates) 
+2.1 (aged 15.7 
years) 
+4.6 (aged 16.7 
years) 
+1.4 (aged 18 
years) 
Not reported Total hip 1.76 





−2.13 (aged 15 
years) 
−1.3 (aged 5 
years) 
Normal −0.4 (aged 11.5 
years) 
1.0 (aged 17.4 
years) 
1.7 (aged 5.7 
years) 
4.2 (aged 28.8 
years) 
0.0 (aged 9.4 
years) 
−3.0 (aged 3.7 
years) 
Age matched DXA Z 
score (post- 
bisphosphonates) 


















0.1 (aged 8.1 
years) 
Sclerae White White Blue-grey White White Blue Blue White White White White White 
Teeth No DI No DI No DI No DI No DI No DI No DI No DI No DI No DI No DI No DI 
Hearing Normal Not reported Not reported Normal Normal Not reported Not reported Not reported Not reported Not reported Not reported Not reported 
Vision Not reported Not reported Not reported Not reported Not reported Not reported Not reported Not reported Not reported Not reported Not reported Not reported 
Hypermobility Hyperlaxity Elbow, wrist, 
interphalangeal 
joints 





Not reported Not reported Not reported Joint hyperlaxity 
(continued on next page) 
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very severe form of the disease, initially being diagnosed with the lethal 
type antenatally. He has continued to have fractures and problems with 
deformities throughout his life. He was also the only patient from this 
cohort to have a significantly low BMD. In contrast to this, patients 5 and 
6 (son and mother respectively) had much milder forms of the condition. 
Bone biopsies were taken from patient 3 (Pepe et al., 2018) and nano-
indentation was performed. The study was limited as the exact location 
that the specimen was extracted from was not comparable to published 
normative paediatric literature. The results showed that the elastic 
modulus and hardness of the bone specimen were lower than those in 
healthy adult bone and the elastic modulus was lower than results from 
other paediatric patients with type III and type I OI. The results also 
showed that the mechanical properties were very heterogeneous across 
different regions of the specimen, and one side of the bone specimen 
showed a larger proportion of denser cortical bone compared to the 
other side. Further bone biopsy samples from this group were difficult to 
obtain, limiting the possibility of generalising the findings. Nevertheless, 
future analysis on a larger sample size should shed more light into bone 
material properties in this group of patients with OI. In addition, evi-
dence of enhanced osteoclastic activity through analyses of urinary 
collagen derived crosslinks and studying osteoclastic activity in bone 
fragments from surgical bone tissue may provide further data on those 
patients that might benefit from bisphosphonate therapy and those that 
may become hypermineralised. 
Patients 4 and 5 were both found to have significantly raised BMD. In 
patient 4 this was significant enough to be remarked upon by the 
operating surgeons who were finding that the bones were particularly 
difficult to drill in to due to their high density. While patients 5 and 6 
shared the same familial variant, Patient 6 did not have a high BMD, 
instead it was consistently normal. 
The phenotypes of patients with mutations in the BMP1 has been 
described as high mineral bone density associated bone fragility (Pollitt 
et al., 2016), but the phenotypes do differ in the literature. It has been 
noted that some patients with milder phenotypes had a homozygous 
variant (c.*241T>C) which only affected the transcription of the BMP1 
protein, leaving the mTLD protein functional. There were also milder 
phenotypes demonstrated in patients with the p.Gly12Arg signal peptide 
variants and 2, out of the 3 patients with this variant, had high bone 
mass. This was thought to be due to a higher mineral incorporation in 
the bone matrix following a delay in bone mineralisation (Syx et al., 
2015). Biopsies that were carried out from patients with BMP1 variants 
and high BMD demonstrated that there was a simultaneous excess of 
osteoid (hyperosteoidosis) and increased mineralisation (hyper-
mineralisation). This was the same as was seen in those with variants in 
the C-propeptide cleavage site (Cundy et al., 2018). 
This cohort of patients included 2 patients with variants in the BMP1 
gene. Despite differing initial presentations, where patient 2 had a fairly 
complicated path to diagnosis, they both did have many similarities. 
They both began getting fractures once they were independently 
mobilising, although in patient 2 this did not occur until later largely due 
to problems with hip dislocation and hypermobility. They also both 
began with light blue sclerae which became white with age and had 
notable scoliosis when older. Both had increased BMD; however, this 
was a more significant finding in Patient 2 who was investigated for 
osteopetrosis early on in her presentation. 
Bisphosphonates are the main pharmacological treatment used in 
children with OI. They work by inhibiting the activity of osteoclasts and 
inducing apoptosis. They have been shown to increase bone mass and 
improve the internal structure of bone tissue, thereby helping to reduce 
the incidence of fractures (Rossi et al., 2019). There is some suggestion 
of delayed healing following surgery in patients having bisphosphonate 
therapy (Marom et al., 2020). Studies have shown that along with 
reducing the rate of fractures, it increases the bone mineral density 
(Bradbury et al., 2012); but does not alter bone mineralisation density 
distribution i.e. tissue bone density (Boyde et al., 1999). 




















































































































































































































































































Clinical phenotype in patients with COL1A1/A2 C-propeptide variants and comparison to published literature.  
Patient 3 4 5 6 26 27 28 29 30 31 32 
Family 3 4 5 5 21 22 23 24 24 25 25 
Source This cohort (Lindahl et al., 2011) (Mcinerney- 
Leo et al., 
2015) 
(Rolvien et al., 2018) (Le Quesne Stabej et al., 2017) 
Age (at time of 
publication) 
12 9 10 30 13.5 14 Not reported 80 56 Not reported Not reported 
Sex M M M F F M F F F F M 
Ethnicity Caucasian Caucasian Caucasian Caucasian Swedish Caucasian 
American 
Not reported Not reported Not reported Pakistani Pakistani 
Consanguinity No No No No Not reported No Not reported Not reported Not reported Yes Yes 
Family history History of #s in 
half sister 
Paternal side Mother (6) Son (5) 
Possibly on 
paternal side 








Uncomplicated Uncomplicated Data unavailable Uncomplicated Uncomplicated Not reported Not reported Not reported Not reported Not reported 
Gestation 37 weeks 40 + 4 weeks 38 weeks Data unavailable Full term NVD Full term NVD Not reported Not reported Not reported Not reported Not reported 
Birth weight 2440 g 3855 g 3400 g Data unavailable 2950 g 3690 g Not reported Not reported Not reported Not reported Not reported 
1st fracture In utero/birth 3 days 2 years 2 months 
Left femur 
Data unavailable 3.5 years right 
tibia and fibula 
2 years Early 
childhood 







1 week 6 weeks–5 years 
Restarted at 8 
years 11 months 




Not reported Not reported Not reported 
Gene COL1A1 COL1A1 COL1A1 COL1A1 COL1A1 COL1A2 COL1A1 COL1A2 COL1A2 COL1A1 COL1A1 
Genotype c.4160C>T c.4343G>A c.3584delG c.3584delG c.3655G>A c.3355G>A c.G3652A c.3359A>G c.3359A>G c.3652A>G c.3652A>G 
Protein change p.Ala1387Val p.Gly1448Asp p.Gly1195fs p.Gly1195fs p.Asp1219Asn p.Ala1119Thr p.Ala1218Thr p.Asp1120Gly p.Asp1120Gly p.Ala1218Thr p.Ala1218Thr 
Heterozygous Heterozygous Heterozygous Heterozygous Heterozygous Heterozygous Heterozygous Heterozygous Heterozygous Heterozygous Heterozygous Heterozygous 
Cognitive 
development 
Normal Normal Normal Data unavailable Normal Not reported Not reported Not reported Not reported Not reported Not reported 
Motor development Very delayed Age appropriate 
by 16 m 
Delayed 
Walking at 21 m 
Data unavailable Normal Not reported Not reported Not reported Not reported Not reported Not reported 
Motor skills Using a walking 
frame at 9 ½ years 








Not reported Not reported Not reported Not reported Not reported Not reported Not reported 
Age match DXA Z- 
score (pre- 
bisphosphonates) 
None measured None measured 0.334 g/cm2 
(aged 16 months, 
no Z score 
available) 
Data unavailable +3.9 (aged 12.5 
years) 
Not reported 7.7 (aged 28) Not reported Not reported BMAD 
0.45 (aged 5 years) 
2.63 (aged 7 years) 
Data not 
available 
Age matched DXA Z 
score (post- 
bisphosphonates) 
−2.1 (aged 10 
years 3 months) 
+0.6 (aged 8 
years 11 months) 
+2.0 (aged 10 
years) 




0.00 (aged 12 
years) 
Not reported Hip +3.9 
Spine normal 
No significant 





change since on 
bisphosphonates 
Not reported Not reported 
Sclerae Grey Blue Blue Blue White Light grey White White White White Not reported 
Teeth Dentinogenesis 
imperfecta 
No DI Normal Data unavailable No DI No DI No DI 
Delayed 
eruption 
No DI No DI No DI but dental 
caries 
Not reported 




Vision Normal Normal Normal Not reported Not reported  Not reported Not reported Not reported Not reported 
(continued on next page) 
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bisphosphonate treatment, all started on pamidronate and most 
showed an increase in BMD following this. It is expected that there 
would be some increase with treatment (Bradbury et al., 2012) and 
patient 6 showed dense vertebral end plates, consistent with 
bisphosphonate use. However, in the cohort described above patient 2 
increased much more significantly following the start of bisphospho-
nate treatment compared to the others. In this cohort, it was often 
found that the treatment was helping with back pain and multiple 
patients noticed increased discomfort in the period leading up to the 
next treatment session. Most of the patients appeared to have a reduced 
rate of fractures following the treatment, but it is not clear whether 
treatment actually reduced fracture risk, or whether fractures just 
decreased with age. Many of the cohort had their dose reduced or 
stopped altogether as their BMD continued to increase. Others were 
stopped when, after a period of having to stop them for surgical/ 
pregnancy related reasons, it was noticed that they had not had any 
increase in fractures. 
5. Conclusions 
This project aimed to establish whether there was a common 
phenotype in OI patients with BMP1 or C-propeptide variants, partic-
ularly in regards to a high bone mass presentation in order to aid de-
cision making when considering treatment in this cohort of patients. 
This cohort shows that 2/2 BMP1 patients and 2/4 C-propeptide 
patients have a high bone mass phenotype; however, it remains unclear 
why some patients do not have high bone mass and why the phenotypes 
can range so greatly. 
We show that some patients with these variants have a significant 
increase in BMD following bisphosphonate treatment that often exceed 
the upper limit of the normal range. Further work is required in a larger 
cohort of patients to establish whether this increase would have 












































































































































































































































































































































































































































  Table 3 Genotype of reported patients in this cohort.  
Patient Variants Classification Variant interpretation 




PM2, PM3, PP4_mod, BP4 
















PM2, PP3, PP2, PS2 = Class 
4. 




PM2, PM5_sup, PP3, PP2, 








Pathogenic PM2, PVS1 = Class 5 
ACMG criterion applied: PS2: De novo (both maternity and paternity confirmed) 
in a patient with the disease and no family history, used at strong level; PVS1: 
null variant (nonsense, frameshift, canonical ±1 or 2 splice sites, initiation 
codon, single or multiexon deletion) in a gene where LOF is a known mechanism 
of disease; PM1: Located in a critical functional domain without benign varia-
tion, used at moderate level; PM2: Absent from controls in gnomAD database; 
PM3: Detected in trans with a pathogenic variant; PP3: Multiple lines of 
computational evidence support a deleterious effect on the gene or gene product, 
used at supporting level; PP4: Highly specific for a single genetic aetiology; PM4- 
M: Protein length changes as a result of in-frame deletions/insertions in a non- 
repeat region or stop-loss variants, used at moderate level; BP4: Multiple lines 
of computational evidence suggest no impact on gene or gene product, used at 
supporting level. 
a No corresponds to patient number. 
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phenotype, regardless of bisphosphonate treatment or whether these 
genotypes give the patients an increased susceptibility and elevated 
sensitisation to treatment with bisphosphonates and if this may be 
agent-specific. A more systematic phenotyping of this group of patients 
from early clinical presentation with close monitoring of response to 
treatment is required to draw further conclusions regarding timing of 
intervention and whether alternate modalities of emerging treatment 
options for OI needs to be considered in this cohort. 
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